ASH/FDA update on Idarucizumab



This webinar recording discusses the U. S. Food and Drug Administration's accelerated approval of idarucizumab for the treatment of patients given dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures, or in life-threatening or uncontrolled bleeding.


  • Jack Ansell, MD, Professor of Medicine, Hofstra North Shore/LIJ School of Medicine, New York, NY
  • Edvardas Kaminskas, MD, Deputy Director, Division of Hematology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD
  • Ken Bauer, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

back to top